Histamine
/api/v1/drug/histamineIndications
Sourced from openFDA- For use as a positive control in evaluation of allergenic (immediate hypersensitivity or "Type I") skin testing.
Contraindications
Sourced from openFDA- Histamine should not be injected into individuals with hypotension, severe hypertension, severe cardiac, pulmonary, or renal disease. Not to be used for diagnosis of pheochromocytoma or to test the ability of the gastric mucosa to secrete hydrochloric acid.contraindicated
Dosage & administration
Sourced from openFDAParenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. For Prick, Puncture and Scratch Testing Histamine base 1 mg/mL (Histamine Phosphate 2.75 mg/mL) should be used to give a reaction. (Refer to Interpretation Section.) Prick, Puncture or Scratch Test Techniques The skin in the test area should be cleansed with alcohol and air dried. The histamine control skin test solution should be placed at the same site with the other skin test antigens, either on the patient's back or on the volar surface of the forearm. The patient should be placed in a comfortable position before the testing is begun. For the prick test, a sharp needle is used to puncture the skin, but not to draw blood. If the scratch test is used, carefully break or scratch the skin with a sterile scarifier. Do not draw blood. Each scratch should be about 2 mm - 4 mm in length. A small drop of the histamine base 1 mg/mL (Histamine Phosphate 2.75 mg/mL) is placed on the abraded skin site no closer than 4 or 5 cm from an adjacent test site. Some physicians prefer to place the solution on the test area and then prick through the drop with a sharp needle. Use a separate sterile scarifier or needle for each patient. The test should be read at 15 minutes; if a large wheal reaction occurs before that time the test site should be wiped free of histamine.
Warnings & precautions
Sourced from openFDACare must be taken in intracutaneous testing to avoid injection into a venule or capillary. Pull back gently on the syringe plunger and note if blood is drawn. If blood is drawn, withdraw needle and inject into another skin site. Small doses by any route of administration may precipitate asthma in patients with bronchial hyperactivity. This product is not intended for inhalation, or subcutaneous injection. The utmost caution is advised in using histamine in such patients and in those with a history of bronchial asthma.
Adverse reactions
Sourced from openFDALocal: Reactions such as wheal, erythema and localized pruritus are to be expected, but if very large (i.e. greater than 4+ as described dosage and administration) may be the first manifestation of a systemic reaction. Systemic: Following the injection of large doses of histamine, systemic reactions may include flushing, dizziness, headache, bronchial constriction, urticaria, asthma, marked hypertension or hypotension, abdominal cramps, vomiting, metallic taste, and local or generalized allergic manifestations (see also OVERDOSAGE ).
Use in specific populations
Sourced from openFDAPregnancy Category C It is not known whether Histamine can cause fetal harm when administered during pregnancy or whether it can affect reproduction capacity. Histamine should be given during pregnancy only if clearly needed. There are no adequate and well-controlled studies during pregnancy. However, based on histamine's known ability to contract uterine muscle, exposure or repeated doses should be avoided. HISTATROL ® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus or mother.
Overdosage
Sourced from openFDAA large subcutaneous dose of Histamine Phosphate may cause severe occipital headache, blurred vision, anginal pain, a rapid drop in blood pressure, and cyanosis of the face. Overdosage may cause severe symptoms including vasomotor collapse, shock, and even death. Epinephrine Injection 0.01 mg/kg to a maximum of 1.0 mg given subcutaneously or intramuscularly should be used in case of emergency due to severe reactions (see Precautions ). An antihistamine preparation may be given intramuscularly to ameliorate systemic reaction to overdose.
FAERS reports
- 1False Negative Investigation Result5221%
- 2Drug Ineffective3916%
- 3Pruritus187.2%
- 4Cough166.4%
- 5Headache166.4%
- 6Rash145.6%
- 7Back Pain135.2%
- 8Diarrhoea135.2%
- 9Dyspnoea135.2%
- 10Anaphylactic Reaction124.8%
- 11Fatigue124.8%
- 12Pain124.8%
- 13Arthralgia114.4%
- 14Dizziness114.4%
- 15Erythema114.4%
Literature
Recent PubMed references pinned to Histamine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Histamine-Mediated Syndrome (HMS): Beyond Allergy and Therapeutic Potential of Immunoglobulin/Histamine Complex (IHC).International journal of molecular sciences · 2026 · Kim HS, Noh GPMID 42196472DOI 10.3390/ijms27104494
- Core-shell inverse opal photonic crystal hydrogel microneedle patch integrating pH and histamine sensing for salmon freshness monitoring.Biosensors & bioelectronics · 2026 · Qiu Y, Liu W, Zhou J, et al.PMID 42176552DOI 10.1016/j.bios.2026.118833
- Cooperative response loops enhanced by histamine signaling during tumor-neutrophil crosstalk in pleural mesothelioma.Cell reports · 2026 · Sueyoshi K, Kakiuchi M, Komura D, et al.PMID 42139053DOI 10.1016/j.celrep.2026.117361
- From Molecular Recognition to On-Site Detection: A Highly Selective Strategy for Monitoring Gizzerosine in Feed by Overcoming Histamine Interference.Journal of agricultural and food chemistry · 2026 · Jiao D, Qian ZJ, Luo L, et al.PMID 42117481DOI 10.1021/acs.jafc.5c14799
- Allergic Rhinitis and Ocular Allergy: A Correlative Study of Serum IgE, Tear Histamine, and Peripheral Eosinophils.Romanian journal of ophthalmology · 2025 · Chaudhary A, Singh JB, Sinha DK, et al.PMID 41971211DOI 10.22336/rjo.2025.85
- Upcycled sericin/coronene/CMC paper: dual-mode colorimetric and LDI-MS histamine detection for fish freshness assessment.Food chemistry · 2026 · Phamonpon W, Hinestroza JP, Rodthongkum N, et al.PMID 41946099DOI 10.1016/j.foodchem.2026.149097
- Histamine and Pruritus: From Molecular Mechanisms to Clinical Therapy.Cell biochemistry and function · 2026 · Lan YA, Guo JX, Yao MH, et al.PMID 41883300DOI 10.1002/cbf.70199
- Histamine Production by Photobacterium spp. in Tuna and Mahi-Mahi under Various Storage Temperatures.Journal of food protection · 2026 · Hayes-Mims M, Baltzer KL, Hyde-Leard E, et al.PMID 41850657DOI 10.1016/j.jfp.2026.100752
Clinical trials
The 10 most recently updated of 338 ClinicalTrials.gov registrations naming Histamine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Recruiting · Phase 1 · Phase 2 · Interventional · 230 enrolled · Merck Sharp & Dohme LLCNCT05319730updated 2026-06-12
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)Recruiting · Phase 3 · Interventional · 770 enrolled · Merck Sharp & Dohme LLCNCT06824467updated 2026-06-12
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)Recruiting · Phase 1 · Phase 2 · Interventional · 190 enrolled · Merck Sharp & Dohme LLCNCT07286149updated 2026-06-12
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)Recruiting · Phase 3 · Interventional · 2,400 enrolled · Merck Sharp & Dohme LLCNCT06966700updated 2026-06-12
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid TumorsRecruiting · Phase 1 · Interventional · 146 enrolled · EpkinNCT06789172updated 2026-06-11
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)Active not recruiting · Phase 3 · Interventional · 520 enrolled · Merck Sharp & Dohme LLCNCT06305754updated 2026-06-09
- Pseudoallergen-Free and Low-Histamine Diet in Adolescents With Chronic Spontaneous UrticariaEnrolling by invitation · Interventional · 120 enrolled · Istanbul UniversityNCT07632040updated 2026-06-08
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)Recruiting · Phase 2 · Interventional · 36 enrolled · The Methodist Hospital Research InstituteNCT05660083updated 2026-06-04
- Famotidine and Antacids for Treatment of DyspepsiaRecruiting · Phase 4 · Interventional · 80 enrolled · Stony Brook UniversityNCT06241183updated 2026-06-02
- Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)Recruiting · Phase 2 · Interventional · 60 enrolled · Merck Sharp & Dohme LLCNCT06788912updated 2026-06-01
Frequently asked questions
- What is Histamine used for?
- According to FDA labeling, Histamine carries indications including: For use as a positive control in evaluation of allergenic (immediate hypersensitivity or "Type I") skin testing.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What are the brand names for Histamine?
- Histamine is marketed under brand names including ActivOn Arthritis, Alo.
- What are the contraindications for Histamine?
- Histamine labeling lists contraindications including: Histamine should not be injected into individuals with hypotension, severe hypertension, severe cardiac, pulmonary, or renal disease. Not to be used for diagnosis of pheochromocytoma or to test the ability of the gastric mucosa to secrete hydrochloric acid.. Always consult the full prescribing information and a clinician.
histamine is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.